Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs. Warfarin in Patients With Mechanical Heart Valves
NCT07456085Phase 3Enrolling by invitation
- Sponsor
- Rawalpindi Institute of Cardiology
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rivaroxaban in valvular heart disease (VHD) (2 arms), sponsored by Rawalpindi Institute of Cardiology. Primary endpoint: Incidence of Thromboembolic Events at 12 months. Started Nov 2025; status: enrolling by invitation.
02
Drugs
rivaroxaban
03
Conditions
valvular heart disease (VHD)
Beyond the preview
Go deeper on NCT07456085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456085.